Wyeth Warning Letter Reflects Continued Difficulties With Hormone Manufacturing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cites the company for GMP violations involving the oral contraceptive Triphasil-28 and Prempro, which has had a slew of recalls in recent years.
You may also be interested in...
FDA Completes Wyeth Guayama Inspection But Has Remaining Concerns
Wyeth will provide update on the status of products under review at the agency on April 19.
FDA Completes Wyeth Guayama Inspection But Has Remaining Concerns
Wyeth will provide update on the status of products under review at the agency on April 19.
Wyeth Anticipates “Approvable” Letter For Effexor XR Follow-On
CEO Essner says issues at firm’s Puerto Rico manufacturing facility are one reason to expect an approvable letter.